Intrexon reported $0 in Loan Capital for its fiscal quarter ending in June of 2024.





Loan Capital Change Date
Agenus USD 153.98M 15.68M Mar/2026
Alaunos Therapeutics USD 4.47M 5.85M Jun/2022
Amgen USD 51.61B 250M Sep/2026
Arrowhead Research USD 824.07M 401.34M Jun/2026
AstraZeneca USD 28.8B 2.79B Sep/2026
Bristol-Myers Squibb USD 41.85B 244M Sep/2026
Gilead Sciences USD 23.82B 17M Sep/2026
GlaxoSmithKline GBP 21.7B 7.75B Sep/2026
Heron Therapeutics USD 140.64M 975K Dec/2025
Incyte USD 28.42M 994K Jun/2026
Intrexon USD 0 198.67M Jun/2024
Karyopharm Therapeutics USD 264.49M 13.73M Mar/2026
Ligand Pharmaceuticals USD 1.13B 679.7M Jun/2026
MacroGenics USD 163.16M 94.44M Jun/2026
MannKind USD 541.7M 3.43M Sep/2026
Merck USD 49.69B 1.39B Sep/2026
Novartis USD 38.38B 893M Sep/2026
Rigel Pharmaceuticals USD 0 0 Sep/2024
Roche Holding CHF 25.22B 2.21B Jun/2026
Sangamo BioSciences USD 0 0 Jun/2022
Thermo Fisher Scientific USD 39.11B 73M Sep/2026
Veracyte USD 0 0 Mar/2025
Xencor USD 71.93M 5.61M Sep/2026